Mental Health. Clarity. Balance.
Depression

Why Depression Subtypes Matter: 25 Years of Clinical Lessons

Explore 25 years of clinical lessons on depression subtypes, covering diagnosis, treatment, and the importance of precision psychiatry.

Why Depression Subtypes Matter: 25 Years of Clinical Lessons

Clinical, Research, and Educational Relevance

In my career as a clinical psychiatrist, clinical trialist, and medical educator, I strive for superior diagnostic precision. In clinical settings, correctly identifying the syndrome and subtypes depends on rigorous evaluation. This evaluation directs the therapeutic plan and predicts disease course. In the lab, the same subtyping logic reduces uncontrolled variability among study participants. In the classroom, this classification structures complex phenomenology to ease learning.

Subtyping depression has direct relevance for patient care, clinical trial design and validity, biomarker discovery, education, and communication with patients and other healthcare providers.

The Active Process of Subtyping

To illustrate how subtyping depression during a clinical evaluation is an active process, I describe how I apply deductive and systems thinking in clinical practice. This involves the iterative refinement of diagnostic subtypes during a psychiatric evaluation.

In a case where a patient seeks help for depression (excluding psychosis, bipolar disorder, and postpartum depression), the next step is establishing severity. Symptom burden and associated psychosocial disability are the data used to categorize depression as mild, moderate, or severe.

Establishing Severity and the PHQ-9

Because we practice measurement-based care and administer the PHQ-9 questionnaire at every evaluation, this score integrates with other data regarding experiences, emotional distress, cognitive effects, and impact on relationships and work. These composite data support a differentiated diagnosis.

Like anxiety, insomnia is among the most distressing symptoms of depression. Although not a defined subtype in DSM-5, prominent sleep symptoms and circadian disruptions must be considered a clinical subtype for two reasons: (1) the primacy of sleep health and circadian rhythm for quality of life, and (2) as a marker of treatment response heterogeneity.

Sleep, Circadian Rhythms, and Suicidality

Interrogation regarding acute and chronic suicidal ideation and behaviors (distinct from death wish), though not a DSM-5 diagnostic subtype, helps refine understanding of the clinical presentation and level of emotional pain. This informs clinical decisions, treatment, and safety planning.

Specific therapeutic considerations for subtypes include prescribing esketamine (the only FDA-approved treatment for patients with MDD and acute suicidality) or escalating the level of care.

Given that there are 227 possible ways to meet the syndromal criteria for MDD including at least 1 of the 2 cardinal symptoms, I consider the following additional subtypes to guide medications, psychotherapy, and interventional procedure planning: (1) depression with anhedonia predominance, (2) depression with sadness predominance, (3) melancholic depression (worse in the morning, prominent neurovegetative symptoms; psychomotor retardation), and (4) atypical depression (rejection sensitivity, fatigue, overeating).

Additional Subtypes for Treatment Guidance

This systematic application of deductive reasoning helps establish whether the patient has syndromal depression, subthreshold depressive disorder, adjustment disorder or dysthymia, seasonal affective disorder, depression with acute or chronic suicidality, melancholic depression, atypical depression, anxiety distress, depression with prominent insomnia/circadian issues, and whether the cardinal symptoms are more likely anhedonia, sadness, or both.

After considering the observed and reported phenomenology (from patient and family), I determine if this is a single (or first) episode of depression, or if the patient has a recurrent form of the illness. I also collect information about the number of medications, psychotherapies, and brain stimulation attempts tried in this and prior episodes, to subtype the presentation as treatment-resistant depression (or my preferred term: hard-to-treat depression).

Recurrence, Treatment Resistance, and Geriatric Considerations

Subtyping the frequency or chronicity of depression and response to prior attempts guides: (1) the recommended duration of treatment (i.e., does this patient need maintenance pharmacotherapy because they have recurrent depression?), and (2) therapeutic approaches with a new mechanism.

Finally, as a geriatric psychiatrist caring for patients with multiple medical problems and neurodegenerative diseases, I subtype the depression phenomenology as possibly linked to a medical condition and/or associated with neurodegenerative changes in the brain.

Final Thoughts

In the absence of validated biomarkers to confirm any of these subtypes and to guide biologically based treatment selection (except biomarkers associated with diseases that often present with depression, such as Alzheimer's disease; uncontrolled endocrine conditions like diabetes, thyroiditis, or parathyroid disease; certain cancers like pancreatic cancer; drug use tests with associated symptoms; and diagnosed obstructive sleep apnea), does improving depression subtyping improve patient outcomes, or is it just an exercise in deductive reasoning and mental model creation?

There are several reasons why depression subtyping improves outcomes. These include: (1) safety and self-harm risk analysis, (2) treatment duration planning based on frequency or chronicity, (3) selection of appropriate psychotherapy, (4) consideration of fluid, imaging, or polysomnography biomarkers to diagnose or monitor other medical or neurological conditions that may cause or worsen depression or interfere with treatment response.

More stories:

Share:

Leave a comment